mesna / Generic mfg. - LARVOL DELTA

Single Center Retrospective Evaluation of Exogenous Albumin Administration for the Prevention of Ifosfamide-Induced Encephalopathy (HOPA 2026) - "Ifosfamide-induced encephalopathy (IIE) occurs in approximately 10–30% of patients, with clinical manifestations ranging from mild confusion to seizures or coma.1 IIE contributes to significant morbidity, treatment delays, and prolonged hospitalization.2 Although the exact mechanism remains unknown, the neurotoxic metabolite chloroacetaldehyde is believed to disrupt mitochondrial respiration and contribute to encephalopathic symptoms.3 Reported risk factors for IIE include advanced age, hypoalbuminemia, renal or hepatic impairment, poor performance status, higher ifosfamide doses, and shorter infusion durations.2,3,4 Prophylactic albumin has been administered with ifosfamide-based regimens to elevate serum albumin and potentially bind circulating neurotoxic metabolites; however, supporting evidence remains limited.5 The University of Colorado Health System utilizes a standardized MAI regimen (Mesna, Adriamycin [Doxorubicin], Ifosfamide), a modified version of the..."

Retrospective data • CNS Disorders • Epilepsy • Hepatology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Outcomes of Sirolimus vs Tacrolimus After Allogeneic Stem Cell Transplantation Using Mycophenolate/Post-Transplant Cyclophosphamide Conditioning (HOPA 2026) - "Calcineurin inhibitors (CNIs), such as cyclosporine A (CsA) and tacrolimus, have traditionally formed the backbone of immunosuppressive therapy in this context... The nonmyeloablative conditioning regimen consisted of fludarabine administered on days −6 through −2 and cyclophosphamide given on day −6 with mesna support, followed by total body irradiation delivered on day −1, with stem cell infusion occurring on transplant day 0. For GVHD prophylaxis, PTCy was administered on days +3 and +4, after which sirolimus and mycophenolate mofetil were initiated on day +5...Leukopenia remained the main adverse event but was generally controllable. Next step is evaluating tacrolimus within the same framework to compare safety and engraftment outcomes more directly."

Post-transplantation • Dyslipidemia • Graft versus Host Disease • Hematological Disorders • Immunology • Leukopenia • Thrombocytopenia • Transplantation

Efficacy of blinatumomab use in B-cell acute lymphoblastic leukemia (ALL) patients with discordant minimal residual disease (MRD) monitoring assays (HOPA 2026) - "Eligible patients received HyperCVAD as induction therapy, consisting of alternating A cycles (cyclophosphamide, mesna, doxorubicin, vincristine, and dexamethasone) and B cycles (high-dose methotrexate and cytarabine). The primary outcome was complete MRD response by NGS following one to two cycles of blinatumomab, assessed through manual chart review. Results/Discussion/Conclusion (State if not available): This study is ongoing therefore results, discussion, and conclusions are not yet available."

Clinical • Discordant • Minimal residual disease • Residual disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia

PATIENTS WITH MULTIPLE SCLEROSIS ABOVE AGE 60 HAVE NEUROLOGICAL RESPONSES TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTS SIMILAR TO YOUNGER INDIVIDUALS: A SINGLE-CENTER EXPERIENCE (EBMT 2026) - "This protocol combines high-dose cyclophosphamide (200 mg/kg), rituximab 1 000 mg, filgrastim, and MESNA. Employing the "Mexican Method," PRR after aHSCT was 75.3%, with no significant difference between age groups. Although older patients had slightly more early complications, overall outcomes were similar, suggesting that age > 60 should not preclude aHSCT in MS."

Clinical • Bone Marrow Transplantation • CNS Disorders • Immunology • Inflammation • Multiple Sclerosis • Transplantation

ACCESS: HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (clinicaltrials.gov) - P2 | N=300 | Active, not recruiting | Sponsor: Center for International Blood and Marrow Transplant Research | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Oncology • Transplantation • HLA-B • HLA-C • HLA-DPB1 • HLA-DQB1 • HLA-DRB1

ROOM TO SPARE? A PRIMARY CARDIAC ANGIOSARCOMA OCCUPIES THE RIGHT ATRIUM (ACC 2026) - "He recovered well postoperatively, received 6 cycles of doxorubicin/ifosfamide/mesna, and at 6 months has remained clinically stable without progression. Primary cardiac angiosarcoma has a median survival of less than 15 months. Early recognition of complications such as mechanical obstruction, arrhythmias and tamponade is critical, and a multimodal strategy with surgery and chemotherapy offers the best opportunity to extend survival."

Angiosarcoma • Cardiovascular • Cognitive Disorders • Heart Failure • Hepatology • Pulmonary Disease • Pulmonary Embolism • Sarcoma • Solid Tumor • Thrombosis

CRITICAL COMPRESSION: SYNOVIAL SARCOMA OF THE MEDIASTINUM BETWEEN THE GREAT ARTERIES (ACC 2026) - "He underwent 6 cycles of Adriamycin, Ifosfamide and mesna, achieving complete symptom resolution. This is a rare case of a high-grade synovial sarcoma diagnosed using multi-modality imaging in the anterior mediastinum with severe PA outflow obstruction and critical left main occlusion successfully managed with chemotherapy alone, obviating surgical resection."

Cardiovascular • Pulmonary Disease • Sarcoma • Solid Tumor • Synovial Sarcoma

Circadian modulation of chemotherapy tolerance and inflammatory response in soft-tissue sarcoma: A real-world analysis of 55 patients (Sarcoma-RC 2026) - "Epirubicin-based chemotherapy remains a standard approach in advanced STS, often combined with ifosfamide, mesna, or gemcitabine. Legal entity responsible for the study Oncology Centre in Burgas LTD, Bulgaria. Funding Has not received any funding."

Clinical • Real-world • Real-world evidence • Breast Cancer • Colorectal Cancer • Mucositis • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

HAP2HCT: TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (clinicaltrials.gov) - P2 | N=69 | Active, not recruiting | Sponsor: St. Jude Children's Research Hospital | N=140 ➔ 69 | Trial completion date: Aug 2025 ➔ Jun 2026

Enrollment change • Trial completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Myeloid Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Hodgkin Lymphoma • Juvenile Myelomonocytic Leukemia • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • AFDN • CBFA2T3 • CREBBP • DEK • ETV6 • FLT3 • GLIS2 • HOXA9 • KAT6A • KDM5A • KMT2A • MLLT10 • NSD1 • NUP214 • NUP98 • RUNX1 • WT1

APPROVED AND EMERGING OPTIONS FOR ONCOLOGY TREATMENT-RELATED TOXICITIES: A TARGETED LITERATURE REVIEW OF THE LANDSCAPE AND REMAINING UNMET NEEDS (ISPOR 2026) - "Agents were cataloged by intended use: (a) rescue therapies for acute overdose or early severe toxicity (e.g., glucarpidase, uridine triacetate, leucovorin rescue); (b) prophylactic organ-protective agents (e.g., mesna, amifostine, dexrazoxane, sodium thiosulfate, palifermin, trilaciclib); (c) countermeasures for immune-mediated toxicities (e.g., tocilizumab for cytokine release syndrome); and (d) radiation normal-tissue protectants in development (e.g., superoxide dismutase mimetics, avasopasem [GC-4419]). Across drug classes, agents demonstrated substantial clinical benefit in narrow, time-sensitive indications (e.g., rescue for high-dose methotrexate or fluoropyrimidine toxicity; cardioprotection with dexrazoxane; otoprotection with sodium thiosulfate in pediatric cisplatin-treated patients; and reduced mucositis with palifermin in select HSCT regimens)... Timely rescue administration can improve outcomes for patients experiencing severe treatment-related toxicities...."

Review • Bone Marrow Transplantation • Cardiovascular • Inflammation • Mucositis

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: St. Jude Children's Research Hospital | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2034 ➔ Dec 2035 | Trial primary completion date: Dec 2030 ➔ Dec 2031

Enrollment open • Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Oncology • Pediatrics • Transplantation

A Case of Bilateral Putaminal Changes in Ifosfamide-induced Neurotoxicity (AAN 2026) - "She was treated with Mesna and methylene blue for suspicion of ifosfamide toxicity. This case highlights a rare but serious neurotoxic complication of ifosfamide chemotherapy. It emphasizes that transient DWI changes in bilateral putamen may initially be misleading for a cerebrovascular process. Hence, repeat imaging is imperative to show resolution of DWI changes."

Clinical • Cardiovascular • CNS Disorders • Epilepsy • Ischemic stroke • Respiratory Diseases • Sarcoma • Solid Tumor

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma (clinicaltrials.gov) - P2 | N=41 | Not yet recruiting | Sponsor: St. Jude Children's Research Hospital

New P2 trial • Lung Cancer • Oncology • Osteosarcoma • Pediatrics • Sarcoma • Solid Tumor

PRESERVE I: A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov) - P1/2 | N=12 | Recruiting | Sponsor: Ossium Health, Inc. | Trial completion date: Dec 2026 ➔ Mar 2027 | Trial primary completion date: Feb 2026 ➔ May 2026

First-in-human • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Cutaneous T-cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • Transplantation • HLA-B • HLA-C • HLA-DRB1

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer (clinicaltrials.gov) - P2 | N=41 | Completed | Sponsor: City of Hope Medical Center | Active, not recruiting ➔ Completed

Trial completion • Breast Cancer • Inflammatory Breast Cancer • Oncology • Solid Tumor • Transplantation

Stem Cell Transplantation in Crohn's Disease (clinicaltrials.gov) - P1/2 | N=15 | Recruiting | Sponsor: Cedars-Sinai Medical Center | Trial completion date: Sep 2026 ➔ Sep 2027 | Trial primary completion date: Sep 2026 ➔ Sep 2027

Trial completion date • Trial primary completion date • Bone Marrow Transplantation • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • Transplantation

Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL (clinicaltrials.gov) - P=N/A | N=70 | Not yet recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University

New trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Patients with Multiple Sclerosis Above age 60 Have Neurological Responses to Autologous Hematopoietic Stem Cell Transplants Similar To Younger Individuals: A Single-Center Experience (ACTRIMS Forum 2026) - "Background & Objectives: To evaluate the neurological response of MS patients treated with TCHa using the “Mexican method” (2), focusing on changes in the Expanded Disability Status Scale (EDSS) (3) and stratifying the results by age. This prospective study included 1,438 MS patients treated with the “Mexican method” (high-dose cyclophosphamide, rituximab, dexamethasone, filgrastim, and MESNA) (2). The overall PR rate in people with MS who received aHCT using the "Mexican method" was 75.1%, similar in patients older than and younger than 60 years (4,5). The rate of early procedural complications was slightly higher in patients older than 60 years. Therefore, being older than 60 years should not be considered a reason to deny aHCT to patients with MS."

Clinical • Bone Marrow Transplantation • CNS Disorders • Multiple Sclerosis • Transplantation

CD45RA-depleted CD19-CAR T Cell Consolidation After TCR??+ T Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: St. Jude Children's Research Hospital | Initiation date: Dec 2025 ➔ May 2026

Trial initiation date • Hematological Malignancies • Lymphoma • Oncology • Pediatrics • Transplantation

Impact of Fluid Shortage on Incidence of Hemorrhagic Cystitis in Patients Receiving Post-Transplant Cyclophosphamide Graft-Versus-Host Disease Prophylaxis (TCT-ASTCT-CIBMTR 2026) - "The IV fluid restriction protocol included continuous mesna with a change from weight-based fluid rate to a standard rate which led to approximately 3.5 liters of normal saline per day of HD cyclophosphamide and 500 milliliters on the following day. Conclusion Management protocols in any future IVF shortages should seek to limit the changes in hyperhydration protocols for patients receiving HD cyclophosphamide including PTCy. - Describe irrigation fluid shortage and protocol adjustments for cellular therapy - Analyze incidence of hemorrhagic cystitis in allogenic stem cell transplantation - Evaluate impact of fluid shortage on hemorrhagic cystitis incidence in allogeneic stem cell transplantation"

Clinical • Post-transplantation • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Septic Shock • Transplantation

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma (clinicaltrials.gov) - P1 | N=6 | Active, not recruiting | Sponsor: Washington University School of Medicine | Phase classification: P1/2 ➔ P1 | N=35 ➔ 6 | Trial completion date: Jan 2029 ➔ Mar 2028 | Trial primary completion date: Jan 2027 ➔ Mar 2026 | Recruiting ➔ Active, not recruiting

Enrollment change • Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

OPTIMIZE: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis (clinicaltrials.gov) - P2 | N=313 | Active, not recruiting | Sponsor: Center for International Blood and Marrow Transplant Research | Recruiting ➔ Active, not recruiting

Enrollment closed • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Chronic Myelomonocytic Leukemia • Essential Thrombocythemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Transplantation • HLA-B • HLA-C • HLA-DPB1 • HLA-DRB1

Primary Renal Synovial Sarcoma: A Report of a Rare Case and Management Approach. (PubMed, Cureus) - "Postoperatively, the patient received adjuvant chemotherapy with the AIM (doxorubicin, ifosfamide, and mesna) regimen. Given the extreme rarity of PRSS, we discuss the diagnostic challenges, molecular characteristics, and treatment approach adopted at our institution, contributing to the limited but growing body of knowledge on this rare entity."

Journal • Genito-urinary Cancer • Kidney Cancer • Oncology • Pain • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Synovial Sarcoma • SS18

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies (clinicaltrials.gov) - P=N/A | N=57 | Active, not recruiting | Sponsor: Masonic Cancer Center, University of Minnesota | Recruiting ➔ Active, not recruiting | N=30 ➔ 57

Enrollment change • Enrollment closed • Bone Marrow Transplantation • Hemophagocytic lymphohistiocytosis • Immunology • Langerhans Cell Histiocytosis • Primary Immunodeficiency • Rare Diseases • Transplantation

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. (PubMed, Lancet Haematol) - P1/2 | "Our data suggest that dose-dense BV-ICE is a rapidly administered and active salvage regimen for patients with relapsed or refractory classical Hodgkin lymphoma despite a complete response in this trial lower than the prespecified phase 2 target. Although cross-trial comparisons should be made with caution, activity results seem to be similar to previously presented brentuximab vedotin chemotherapy salvage combinations delivered over much longer durations and can be considered in young (<60 years), transplantation-eligible patients for second-line therapy."

Clinical • Journal • P1/2 data • Bone Marrow Transplantation • Cardiovascular • Diabetes • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Oncology • Pulmonary Embolism • Respiratory Diseases • Septic Shock • Thrombocytopenia • Transplantation